N-(1-CYCLOPROPYL-2,2,2-TRIFLUOROETHYL)-6-FLUORO-7-(2,4,6-TRIFLUOROPHENYL)PYRIDO[2,3-B]PYRAZIN-8-AMINE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PABVHZQAKJFYIL-UHFFFAOYSA-N
Smiles	Fc1cc(F)c(c(F)c1)c2c(F)nc3nccnc3c2NC(C4CC4)C(F)(F)F
InChI	InChI=1S/C18H11F7N4/c19-8-5-9(20)11(10(21)6-8)12-13(28-15(7-1-2-7)18(23,24)25)14-17(29-16(12)22)27-4-3-26-14/h3-7,15H,1-2H2,(H,27,28,29)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H11F7N4
Molecular Weight	416.3
AlogP	4.73
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	50.7
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity
Antifungal activity against Magnaporthe grisea infected 3 weeks old rice plant assessed as reduction of diseased leaf area treated 2 days before infection measured after 6 days	Magnaporthe grisea	104.0 mg/L
Antifungal activity against Zymoseptoria tritici infected 2 weeks old wheat plant assessed as reduction of diseased leaf area treated 1 day before infection measured after 16 to 18 days	Zymoseptoria tritici	6.0 mg/L
Antifungal activity against Puccinia triticina infected 2 weeks old wheat plant assessed as reduction of diseased leaf area treated 1 day before infection measured after 11 days	Puccinia triticina	16.0 mg/L

Cross References

Resources	Reference
ChEMBL	CHEMBL2286199
PubChem	76320073

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).